Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
Decision support for precision oncology: Evolving from monotherapy to genomically informed combinations

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 378

Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA

Prof Funda Meric-Bernstam speaks to ecancer at the WIN 2019 Symposium in Paris about the use of genomic testing to direct genomically-informed patient care.

She states that the main challenge of this type of testing is the interpretation of results, the increasing appearance of uncommon mutations and access to the different therapeutic options available.

To overcome these challenges, Prof Meric-Bernstam explains that they are putting a platform in place to support oncologists in interpreting these results.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation